Video
Dr. Cremolini on Identifying Molecular Markers in mCRC
Author(s):
Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).
Chiara Cremolini, MD, a medical oncologist at the Tuscan Tumor Institute in Pisa, Italy, discusses the necessary steps researchers must take to identify molecular markers in metastatic colorectal cancer (mCRC).
Cremolini does not believe any clinical trials based on molecular markers can currently be planned, because researchers have not encountered any with promising results. However, she says it is crucial for there to be a collection of biological samples of patients enrolled in the TRIBE-2 trial, a phase III study that will compare first-line FOLFOXIRI plus bevacizumab followed by FOLFOXIRI plus bevacizumab at progression, to FOLFOX plus bevacizumab followed by FOLFIRI plus bevacizumab at disease progression.
A final analysis of this study may allow researchers to answer questions regarding molecular markers in mCRC.
